Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

Delayed Quote. Delayed  - 09/28 10:00:17 pm
42.29 USD   -0.09%
09/28 GLOBAL DRUG ELU : BOSTON SCIENTIFIC, JOHNSON and JOHNSON, ABBOTT LAB..
09/28 ABBOTT LABORATO : Receives FDA Approval for the FreeStyle Libre Pro&..
09/28 ABBOTT : Receives FDA Approval for the FreeStyle Libre Pro(TM) Syste..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Abbott Laboratories : Abbott Receives U.S. FDA Clearance to Use iFS Advanced Femtosecond Laser Technology for Arcuate Incisions in Cataract Surgery

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/20/2012 | 03:05pm CEST

ABBOTT PARK, Ill., April 20, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) announced today U.S. Food and Drug Administration clearance to use its iFS Advanced Femtosecond Laser to create bow-shaped or curved arcuate incisions in corneal surgery, including cataract surgery.

The iFS Laser is currently used to create LASIK flaps and other corneal incisions in the eye and is the fifth generation of IntraLase technology, which has been used in more than 5 million procedures worldwide.

Nearly 3 million patients undergo cataract surgery each year in the United States. With this new clearance, the iFS Laser now gives surgeons the ability to make precise, bladeless arcuate incisions during surgery and customize the incision for each individual patient.

Factors such as placement, length, depth and radius of curvature can influence the surgeon's desired change to the cornea. These parameters can be difficult to control through traditional incisions made by hand using surgical knives. Now, using the iFS Laser, arcuate incisions can be performed with greater precision, predictability and customization than is possible with a manual technique.

"This is a major advancement and expansion of our Femtosecond laser technology," said Jim Mazzo, senior vice president, Abbott Medical Optics. "Abbott has been a pioneer in the ophthalmic use of Femtosecond lasers, and this new use of our technology demonstrates our leadership position in this very dynamic and competitive market. This is an important step as we look to utilize Femtosecond laser technology as a potential standard of care during the cataract procedure."

Study data support that the iFS Femtosecond laser creates arcuate incisions safely and effectively as prescribed by the physician, and complies with applicable safety standards.

This new use of Abbott's iFS Femtosecond laser is available now in the United States.

About Abbott Medical Optics (AMO)

Abbott Medical Optics is focused on delivering life-improving vision technologies to people of all ages. The company offers a comprehensive portfolio of cataract, refractive and eye care products. Products in the cataract line include monofocal and multifocal intraocular lenses (IOLs), phacoemulsification systems, viscoelastics, and related products used in ocular surgery. Products in the refractive line include wavefront diagnostic devices, femtosecond lasers and associated patient interface devices; excimer laser vision correction systems and treatment cards. Products in the eye care line include disinfecting solutions, enzymatic cleaners, lens rewetting drops and artificial tears.

For more information, please visit www.abbottmedicaloptics.com.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 91,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.

SOURCE Abbott

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBOTT LABORATORIES
09/28 GLOBAL DRUG ELUTING STENTS (DES) MAR : BOSTON SCIENTIFIC, JOHNSON and JOHNSON, A..
09/28 ABBOTT LABORATORIES : Receives FDA Approval for the FreeStyle Libre Pro™ S..
09/28 ABBOTT : Receives FDA Approval for the FreeStyle Libre Pro(TM) System, a Revolut..
09/21 ABBOTT LABORATORIES : Malnutrition Adds $15.5 Billion Annually to Direct U.S. Me..
09/21 DGAP-NEWS : Abbott Laboratories: Announcement of Intention to Delist
09/21DJABBOTT LABORATORIES : to Delist from London Stock Exchange
09/21 ABBOTT : Hosts Conference Call for Third-Quarter Earnings
09/21 ABBOTT LABORATORIES : MILITARY $38,669 Federal Contract Awarded to Abbott Labora..
09/20 ABBOTT LABORATORIES : Justification and Approval - Abbott Laboratories Chemical ..
09/20 FUELING PERFORMANCE WITH FAT : EAS® Launches First Ketogenic Meal Replacement Fo..
More news
Sector news : Pharmaceuticals - NEC
09/28DJINTRA CELLULAR THERAPIES : Shares Plunge After Disappointing Drug Trial Results
09/28DJGLAXOSMITHKLINE : to Sell Remaining 6.2% Stake in Aspen Pharmacare
09/28 Monsanto ally Novozymes sees opportunity, risk in Bayer merger
09/27DJPFIZER : Scraps Plan to Break Up Company -- WSJ
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress -- 3rd Upd..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/28 FDA OKs Abbott's FreeStyle Libre Pro continuous glucose monitoring system
09/26 Amazon's Next Step Toward Global Domination
09/22 JOHNSON & JOHNSON : From Dead Money To Amongst The Best In My Portfolio
09/21 Presenting Apple's First Car
09/20 A Unique Method To Value Dividend Stocks Based On Expected Growth